Quince Therapeutics, Inc. QNCX

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
51/100
Moderate

Ranked against 712 peers in Biotechnology

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that … Full QNCX analysis →

Key strengths

  • ROIC Sustainably Above Peers ROIC at 95.7th percentile exceeds peers and WACC, demonstrating superior capital allocation.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.34), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.07), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where QNCX ranks in Biotechnology

Quince Therapeutics, Inc. ranks #226 of 713 scored companies in Biotechnology by moat score — the top 32%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
222 Metagenomi, Inc. MGX 51/100 Moderate
223 BiomX Inc. PHGE 51/100 Moderate
224 Immatics N.V. IMTXW 51/100 Moderate
225 Mineralys Therapeutics, Inc. MLYS 51/100 Moderate
226 Quince Therapeutics, Inc. QNCX 51/100 Moderate
227 Brainstorm Cell Therapeutics In BCLI 51/100 Moderate
228 Scholar Rock Holding Corporatio SRRK 51/100 Moderate
229 Rhythm Pharmaceuticals, Inc. RYTM 51/100 Moderate
230 Seer, Inc. SEER 51/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How QNCX scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 68 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 24 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding QNCX's moat

What is Quince Therapeutics, Inc.'s moat score?

Quince Therapeutics, Inc. (QNCX) scores 51 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #226 of 713 scored companies in Biotechnology, the top 32%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (68/100) and its weakest is Resilience (24/100).

How does Quince Therapeutics, Inc. compare with other Biotechnology companies?

Quince Therapeutics, Inc. ranks #226 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Mineralys Therapeutics, Inc. (MLYS) at 51 just above it and Brainstorm Cell Therapeutics In (BCLI) at 51 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Quince Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Quince Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and QNCX scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (68), Resilience (24), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000